Format

Send to

Choose Destination
Leukemia. 2010 Apr;24(4):855-7. doi: 10.1038/leu.2010.7. Epub 2010 Feb 11.

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

PMID:
20147980
DOI:
10.1038/leu.2010.7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center